Tag Archives: european commission

The AgedBrainSYSBIO consortium, a four-year project on brain ageing funded by the European Commission under the Health Cooperation Programme of the 7th Framework Programme, is hosting a public workshop, Normal and pathological brain ageing: from systems biology to the clinic.

The workshop, to be held on October 19, 2016, at the Imagine Institute in Paris, will bring together clinicians, biologists, bioinformaticians and statisticians to present the latest advances in the field.

To view the preliminary programme and register for the workshop, visit the AgedBrainSYSBIO website.

Today the Lancet Neurology Commission released a major report detailing the state of research and patient care for Alzheimer´s disease and other dementias and providing recommendations for the future. The conclusion: A concerted effort and long-term economic commitment are critical to meeting the global challenge of Alzheimer’s disease and other dementias.

The comprehensive report, which was the result of a collaborative effort between more than 30 leading researchers from around the world, will also be presented to the European Parliament Commissioners today in Brussels.

The Lancet Neurology Commission, initiated by Lancet editors, is led by Professor Bengt Winblad of the Center for Alzheimer Research at the Karolinska Institutet in Sweden. Winblad is also a member of the JPND Scientific Advisory Board and was the coordinator of BIOMARKAPD, a JPND project on Biomarkers for Alzheimer’s disease and Parkinson’s disease. Three other members of the JPND Scientific Advisory Board, Prof. Martin Knapp (United Kingdom), Prof. Bruno Dubois (France), and Prof. Philip Scheltens (Netherlands), as well as the Chair of the JPND Management Board, Prof. Philippe Amouyel, participated as experts in this report. The commission was formed with the aim of providing expert recommendations and information to politicians and policymakers about Alzheimer´s disease and related dementias.

The report encompasses the fields of health economics, epidemiology, prevention, genetics, biology, diagnosis, treatment, care and ethics. To reduce the burden of dementia, the commission advocates that public governmental agencies form large multinational partnerships with academic centres and pharmaceutical companies to deploy capital resources and share risk.

“To defeat Alzheimer’s disease and other dementias, united actions are needed, not only within research, but also within the political arena on all levels,” said Winblad. “My hope is that our work will stimulate increased national and international collaboration.”

Alzheimer’s, the most common form of dementia, accounts for approximately 60 percent of cases. The most important risk factor is age, and as life expectancy increases, the number of people with dementia is also expected to rise. In 2015, almost 47 million individuals around the world were estimated to be affected. By 2030, the number is expected to reach 75 million. By 2050, up to 131 million people are expected to be burdened by the disease. So far, no treatment is available to effectively halt or reverse the disease.

Alzheimer’s disease and related disorders are one of the major targets of JPND, which as the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases is cited in the report as an example of the sort of action needed to make meaningful progress. “To speed up progress even more, ” the report asserts, “this global collaboration must be extended to even more countries.”

For Winblad, the onus is now on governments to take action — and quickly: “What we need now is for the politicians to realise that this is a growing problem that already costs society tremendous amounts of money,” he said. “We need investments of resources in research in all areas involved in this disease, to find better drugs, but also to improve compassionate care and prevention.”

Five months into his five-year term as research commissioner, Carlos Moedas spoke to Nature Magazine about his hopes and ambitions for the scientific programmes run by the European Union (EU), particularly the huge seven-year €80-billion (US$86-billion) Horizon 2020 (H2020) research programme, which runs until 2020.

Moedas wants scientists to change their mentality for H2020, breaking free of individual silos and including more social science. But he is already facing complaints that money is being stripped from the programme to finance other European initiatives, such as the proposed €16-billion European Fund for Strategic Investment (EFSI), a Europe-wide bid to stimulate the region’s economy.

An edited version of the interview is available through the link below:

Source: Nature Magazine

The EU Joint Programme – Neurodegenerative Disease Research (JPND) in partnership with the European Commission has launched the ‘JPco-fuND’ call for proposals aimed at supporting transnational research collaborations in three JPND priority areas:

  • Longitudinal Cohort Approaches;
  • Advanced Experimental Models;
  • Risk and Protective Factors.

The call will see more than 30 million euro being made available by JPND member countries, with a 10 million euro European Commission “topping up” fund.

‘Neurodegenerative Diseases such as Alzheimer’s and Parkinson’s are a global health, economic and social emergency with numbers affected expected to double by 2030 and more than triple by 2050’ according to Professor Philippe Amouyel, Chair of the JPND Management Board. ‘With this in mind, JPND-participating countries have identified three further areas of greatest need for targeted investment in order to increase progress in the prevention and treatment of these diseases, as well as in patient care.

Professor Amouyel added ‘This call is launched as part of a major new cohesive action between JPND and the European Commission entitled JPco-fuND – the first concrete synergy between JPND and Horizon 2020 designed to address the global threat of neurodegenerative diseases’.

According to Professor Thomas Gasser, University of Tübingen and Chair of the JPND Scientific Advisory Board, ‘This call aims to pool the necessary expertise across Europe and globally to address these needs in the fight against neurodegenerative diseases. The call will support innovative, multi-disciplinary, collaborative research projects that will add value to the three research areas’.

The following neurodegenerative diseases are included for the three call topics outlined below:

  • Alzheimer’s disease and other dementias
  • Parkinson’s disease and PD‐related disorders
  • Prion diseases
  • Motor neurone diseases
  • Huntington’s disease
  • Spinocerebellar ataxia (SCA)
  • Spinal muscular atrophy (SMA)

Click here to link to the call for proposals webpage

Topic 1: Genetic, epigenetic and environmental risk and protective factors of neurodegenerative diseases

The aim of the first topic is to attract international teams of researchers who will explore the different processes at work in normal aging versus neurodegenerative aging and determine what role genetic and environmental factors can play. Factors such as family history, gender, stress levels, nutrition and others, can affect an individual’s risk, and provide protection from, or even resilience to, neurodegenerative diseases. However, it is likely that a combination of factors are involved, so a critical step will be to establish the relationship between genetic, epigenetic, environmental and social factors and their relative importance in order to identify those factors that can be changed or modified. This topic is a re-launch of the 2012 JPND call in this priority area. Details of the currently-supported JPND projects in this area are available here on the JPND website.

JPND countries participating in this topic (18) Austria, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Luxembourg, The Netherlands, Norway, Portugal, Slovak Republic, Spain, Sweden, Turkey, United Kingdom

Topic 2: Longitudinal cohort approaches in neurodegenerative diseases

The goal of this topic is to further scientific progress at a transnational level by enhancing the capabilities of existing cohort studies, or by linking related cohort studies in a synergistic way. This may include bringing together well-characterised relevant cohort groups to harmonize, or make accessible, data to promote secondary analysis; adding new measurements, sample collections or data sweeps that add significant value or provide linkage to other studies; establishing novel assessment measures, taking advantage of new technologies, extending beyond the cognitive domain (i.e. motor and perceptual function) that can be applied to the broad spectrum of neurodegenerative diseases; delivering methodological developments or enhancements to establish cohorts as intervention platforms.

JPND countries participating in this topic (19) Austria, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Luxembourg, The Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Turkey, United Kingdom

Topic 3: Advanced animal or cell experimental models of neurodegenerative diseases This topic aims to support the creation of experimental models that are more predictive of neurodegenerative diseases. This is a key barrier to progress in research as most of the current models are unable to take into account the multiple genetic and environmental factors that lead to the development of these diseases. However, in order to reproduce the complexity of these diseases there is a need for consensus in validating the platforms to be provided, which can only be achieved through a multidisciplinary approach that encompasses the best teams in a collaborative effort at a transnational level. Therefore, this topic encourages the implementation of a next generation of reliable and well characterized animal and cell models for neurodegenerative diseases. This may include the development of novel animal models for specific diseases to better reproduce the complexity of the clinical features of the disease in humans, the enhancement of existing animal models, e.g., by fostering a deeper characterization of the phenotypes and pathologies, and the exploitation of novel or the improvement of existing neuronal, neuronal-like cells or inducible pluripotent stem (iPS) cells, generated from different sources.

JPND countries participating in this topic (18) Austria, Belgium, Denmark, Finland, France, Germany, Israel, Italy, Luxembourg, The Netherlands, Norway, Poland, Portugal, Romania, Slovak Republic, Spain, Sweden, Turkey

Note 1: The call has a two-step procedure, with a first stage (pre-proposal submission) deadline of 23:59h C.E.T. on March 10th 2015.

Note 2: Proposals may cover more than one of the topics specified above, as long as the relevant work is carried out in a country that will financially support the topic. The balance of awards between the three topics will be decided by the Peer Review Panel and will depend on the quality of the applications. More information on the participating countries in each topic, in addition to specific grant practicalities is available on the call for proposals page here.

Note 3: Call applicants are encouraged to take advantage of the JPND online partnering tool to showcase their research group’s expertise, search for appropriate partners and pitch call-related ideas. An improved, multi-lingual version of the pilot tool is available on the JPND website here.

Note 4: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 643417 – JPcofuND.

The EU Joint Programme – Neurodegenerative Disease Research (JPND) will shortly begin a major new cohesive action with the European Commission – the first concrete synergy between JPND and Horizon 2020 designed to address the global threat of neurodegenerative diseases.

As part of this new initiative, JPND will launch a joint transnational call for proposals in January 2015 aimed at supporting transnational research collaborations in three JPND priority areas:

  • Longitudinal Cohorts
  • Advanced Experimental Models
  • Risk and Protective Factors

The aim of the call is to support a limited number of ambitious, high level, innovative, multi-national and multi-disciplinary collaborative research projects that will add value to the respective research areas.

The call will see more than 30 million euro being made available by JPND member countries, including a significant additional European Commission “topping up” component of up to 30%.

This will be a 2-step call, anticipated to launch in early January 2015, with a likely first stage (pre-proposal submission) deadline of March 2015.

Further detail will be provided at the time of the call launch date in January 2015. However, the indicative titles of each call topic are provided below:

Topic 1: Genetic, epigenetic and environmental risk and protective factors of neurodegenerative diseases:

Due to the phenomenal number of high quality proposals received but unsupported under the 2012 JPND joint transnational call, JPND is re-launching a call topic in this area. Examples of areas covered under this topic again include identification of novel genetic, epigenetic and environmental risk and protective factors associated with neurodegenerative disorders in animal, cell and human studies.

Topic 2: Longitudinal cohorts in neurodegenerative disease research:

The key priority under this topic will be to enhance the capabilities of existing longitudinal cohort studies, or linking related studies to address key questions through a synergistic approach. This topic will aim to build upon the report of the JPND Action Group in this area as well as referencing the ongoing work of the JPND Working Groups, supported under the 2014 JPND “rapid action” call.

Topic 3: Advanced experimental models of neurodegenerative diseases:

This topic will focus on the encouragement of a next generation of reliable and well characterized animal and cell models for neurodegenerative diseases, building upon the report of the JPND Action Group in this area. This may include the development of novel animal models for specific diseases to better reproduce the complexity of the clinical features of the disease in humans, the enhancement of existing animal models (e.g. by fostering a deeper characterization of the phenotypes and pathologies), and the exploitation of novel (or the improvement of existing) neuronal, neuronal-like cells or inducible pluripotent stem (iPS) cells, generated from different sources.

Please Note: 

  • Proposals are not limited to each topic, and may cover two or more topics.
  • JPND countries may support one, two or three call topics so applicants will need to take this into consideration.
  • Call applicants are encouraged to take advantage of the JPND online partnering tool to showcase their research group’s expertise, search for appropriate partners and pitch call-related ideas. An improved, multi-lingual version of the pilot tool is now available here.
  • All information regarding future JPND Call topics is indicative and subject to change.
  • Final call information will be published on the JPND website.

The JPND diseases are:
Alzheimer’s disease (AD) and other dementias, Parkinson’s disease (PD) and PD‐related disorders, Prion disease, Motor neurone diseases (MND), Huntington’s disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA)